A comprehensive view of Immatics N.V.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
Moderna and Immatics partner to leverage Immatics' XPRESIDENT discovery platform and Moderna's mRNA technology to develop novel cancer vaccines; partnership to evaluate Immatics' IMA203 PRAME TCR-T with Moderna's investigational PRAME mRNA cancer vaccine
Published:
September 11, 2023
by Moderna Inc.
|
Ask us about our R&D/Patents market view